[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, Degeest K, Miller BE, Susumu N, Ueland FR: Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study. J Clin Oncol; 2010 Jun 01;28(16):2727-31
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
  • PURPOSE: Platinum and taxane compounds have demonstrated activity in uterine carcinosarcoma (malignant mixed Mullerian tumor).
  • PATIENTS AND METHODS: Eligible patients had advanced stage (III or IV), persistent or recurrent measurable disease, and no prior chemotherapy.
  • Patients received paclitaxel at 175 mg/m(2) intravenously (IV) over 3 hours plus carboplatin (area under the serum concentration-time curve = 6) IV over 30 minutes every 3 weeks until disease progression or until adverse effects occurred.
  • Treatment was well tolerated with expected hematologic toxicity and minimal nonhematologic grade 4 toxicity (one cardiovascular and two pain) with 59% of patients completing six or more cycles of chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinosarcoma / drug therapy. Carcinosarcoma / mortality. Uterine Neoplasms / drug therapy. Uterine Neoplasms / mortality
  • [MeSH-minor] Aged. Aged, 80 and over. Biopsy, Needle. Carboplatin / administration & dosage. Carboplatin / adverse effects. Confidence Intervals. Disease-Free Survival. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Immunohistochemistry. Infusions, Intravenous. Kaplan-Meier Estimate. Maximum Tolerated Dose. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Staging. Paclitaxel / administration & dosage. Paclitaxel / adverse effects. Probability. Prognosis. Program Evaluation. Risk Assessment. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Feb 15;71(4 Suppl):1702-9 [8381710.001]
  • [Cites] J Clin Oncol. 1991 Nov;9(11):1962-6 [1941054.001]
  • [Cites] Gynecol Oncol. 1997 Oct;67(1):70-5 [9345359.001]
  • [Cites] Am J Clin Oncol. 1998 Jun;21(3):306-7 [9626805.001]
  • [Cites] Stat Med. 1998 Oct 30;17(20):2301-12 [9819829.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):526-31 [17290061.001]
  • [Cites] Gynecol Oncol. 2007 Nov;107(2):177-85 [17822748.001]
  • [Cites] Gynecol Oncol. 2008 Jan;108(1):58-62 [17935761.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Gynecol Oncol. 2000 Nov;79(2):147-53 [11063636.001]
  • [Cites] Gynecol Oncol. 2001 Nov;83(2):268-70 [11606082.001]
  • [Cites] Gynecol Oncol. 2002 May;85(2):311-4 [11972393.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):774-8 [15350372.001]
  • [Cites] Ann Intern Med. 1973 Oct;79(4):604-5 [4748282.001]
  • [Cites] Cancer. 1985 Apr 15;55(8):1648-53 [3884128.001]
  • [Cites] J Clin Oncol. 1985 Sep;3(9):1240-5 [3897471.001]
  • [Cites] Am J Clin Oncol. 1985 Oct;8(5):350-2 [3840643.001]
  • [Cites] Biometrics. 1985 Sep;41(3):741-4 [4074823.001]
  • [Cites] Cancer Treat Rep. 1986 Feb;70(2):271-4 [3948191.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):618-21 [3559652.001]
  • [Cites] Cancer Treat Rep. 1987 Jun;71(6):661-2 [3034423.001]
  • [Cites] Cancer. 1989 Mar 1;63(5):935-8 [2914299.001]
  • [Cites] Am J Obstet Gynecol. 1989 Aug;161(2):309-12 [2548382.001]
  • [Cites] Gynecol Oncol. 1989 Sep;34(3):372-8 [2548936.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] Int J Gynecol Pathol. 1990;9(1):1-19 [2152890.001]
  • [Cites] Am J Clin Oncol. 1990 Feb;13(1):32-4 [2154921.001]
  • [Cites] Semin Oncol. 1990 Apr;17(2 Suppl 4):6-10 [2159188.001]
  • [Cites] Invest New Drugs. 1991 Feb;9(1):93-4 [2026490.001]
  • [Cites] Am J Clin Oncol. 1996 Aug;19(4):400-2 [8677914.001]
  • (PMID = 20421537.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA037517; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  • [Other-IDs] NLM/ PMC2881851
  •  go-up   go-down


2. Behtash N, Hashemi R, Karimi Zarchi M: Uterine malignancy following tamoxifen use in breast cancer patients in Iran: case series and literature review. Asian Pac J Cancer Prev; 2009 Jan-Mar;10(1):163-6
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: This study evaluated tumor characteristics and survival in women with breast cancer who subsequently developed uterine cancer.
  • Two cancers were malignant mixed Mullerian tumors of the uterus (MMMT), 2 were endometrioid adenocarcinomas, and one was a papillary clear cell carcinoma.
  • The endometrial cancers occurred 2-11 years after initial treatment for the breast cancers.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Neoplasms, Second Primary / chemically induced. Selective Estrogen Receptor Modulators / adverse effects. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469647.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


3. Magnani KK, Dubey S, Rai S: Malignant mixed Müllerian tumor of the uterus associated with tamoxifen therapy for breast cancer. Indian J Pathol Microbiol; 2010 Oct-Dec;53(4):886-7
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed Müllerian tumor of the uterus associated with tamoxifen therapy for breast cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / complications. Breast Neoplasms / drug therapy. Mixed Tumor, Mullerian / chemically induced. Tamoxifen / therapeutic use. Uterine Neoplasms / chemically induced


Advertisement
4. Ruiz Tovar J, Reguero Callejas ME, Arano Bermejo JI, Capote Armas LF, González-Palacios Martínez F, Cabañas Navarro L: Malignant mixed Mullerian tumors. Clin Transl Oncol; 2006 Feb;8(2):129-32
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed Mullerian tumors.
  • Malignant mixed Mullerian tumours (MMMTs) are rare neoplasms, highly aggressive and with an extremely poor prognosis, usually arising in elderly postmenopausal women and presenting at an advanced stage.
  • MMMTs derive from the mullerian mesodermus that differentiates in epithelial and stromal elements, both malignant elements.
  • The initial manifestations were mainly bloody discharge, abdominal pain and increase of the volume of the uterus.
  • Treatment in 2 patients was hysterectomy with double ooforectomy, and resection of the pelvic mass was the treatment in the third case.
  • Adjuvant radio chemotherapy was administrated in 2 of the 3 cases.
  • [MeSH-major] Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / secondary. Breast Neoplasms / secondary. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Fatal Outcome. Female. Femoral Neoplasms / secondary. Humans. Hysterectomy. Ifosfamide / administration & dosage. Ilium. Middle Aged. Neoplasms, Second Primary. Ovariectomy. Paclitaxel / administration & dosage. Palliative Care. Pelvic Neoplasms / secondary. Pelvic Neoplasms / surgery. Prognosis. Radiotherapy, Adjuvant. Sarcoma, Ewing. Spinal Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chirurgie. 1996;121(3):198-202 [8945826.001]
  • [Cites] J Obstet Gynaecol. 2003 May;23(3):301-3 [12850867.001]
  • [Cites] Br J Obstet Gynaecol. 1983 Jun;90(6):562-9 [6305395.001]
  • [Cites] J Clin Pathol. 2002 May;55(5):321-5 [11986333.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):717-24 [8616764.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):687-90 [12445244.001]
  • (PMID = 16632428.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


5. Takano M, Shibasaki T, Sato K, Aida S, Kikuchi Y: Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma component. Gynecol Oncol; 2003 Nov;91(2):444-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma component.
  • OBJECTIVES: Hepatoid adenocarcinoma is a rare tumor and has the histological coexistence of well-differentiated adenocarcinoma and nests of hepatoid cells with immunoreactivity for alpha-fetoprotein (AFP).
  • A case of hepatoid adenocarcinoma in malignant mixed Mullerian tumor of the uterus is presented with a review of the literature.
  • Histologically, the tumor was composed of endometrioid adenocarcinoma, neoplastic hepatoid cells, and sarcoma component including leiomyosarcoma and rhabdomyosarcoma.
  • After operation followed by six courses of platinum-based chemotherapy, serum levels of AFP dropped into normal range.
  • CONCLUSIONS: This is, to our knowledge, the first report of malignant mixed Mullerian tumor of the uterus with an AFP-producing hepatoid adenocarcinoma component.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Mixed Tumor, Mullerian / metabolism. Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology. alpha-Fetoproteins / biosynthesis

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14599882.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  • [Number-of-references] 17
  •  go-up   go-down


6. Ho SP, Ho TH: Malignant mixed Mullerian tumours of the uterus--a ten-year experience. Singapore Med J; 2002 Sep;43(9):452-6
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed Mullerian tumours of the uterus--a ten-year experience.
  • OBJECTIVES: To review the clinico-pathological features of malignant mixed Mullerian tumours of the uterine corpus, their prognosis and treatment outcome.
  • METHODS: A retrospective study of malignant mixed Mullerian tumours of the uterus seen at KK Women's & Children's Hospital from January 1989 to December 1998.
  • Diagnostic dilatation and curettage obtained the diagnosis in 15 patients.
  • Majority of patients had surgery with adjuvant chemotherapy, while adjuvant radiotherapy was offered only recently.
  • In conclusion, malignant mixed Mullerian tumours of the uterine corpus are aggressive tumours associated with poor prognosis.
  • [MeSH-major] Mixed Tumor, Mullerian / epidemiology. Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / diagnosis. Uterine Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Biopsy, Needle. Chi-Square Distribution. Cohort Studies. Combined Modality Therapy. Female. Humans. Middle Aged. Mixed Tumor, Malignant / epidemiology. Mixed Tumor, Malignant / pathology. Mixed Tumor, Malignant / therapy. Neoplasm Staging. Probability. Prognosis. Retrospective Studies. Risk Assessment. Singapore / epidemiology. Survival Analysis

  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12568422.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Singapore
  •  go-up   go-down


7. Goldman NA, de Los Angeles MM, Jones JG, Goldberg GL: Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene. Obstet Gynecol; 2005 May;105(5 Pt 2):1278-80
Hazardous Substances Data Bank. RALOXIFENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed mullerian tumor of the uterus in a patient taking raloxifene.
  • BACKGROUND: Uterine malignant mixed mesodermal tumor is a rare variant of uterine cancer.
  • We report a case of a women in whom a malignant mixed mesodermal tumor was diagnosed while she was taking raloxifene, which is also a selective estrogen receptor modulator.
  • CASE: A malignant mixed mesodermal tumor was diagnosed in a 64-year-old woman with a bicornuate uterus while she was taking raloxifene for osteoporosis prevention.
  • Diagnosis had been delayed secondary to sampling of the other uterine horn.
  • CONCLUSION: There may be an association between raloxifene and the development of malignant mixed mesodermal tumor.
  • Special attention should be paid when attempting to sample the endometrium in patients with mullerian abnormalities.
  • [MeSH-major] Mixed Tumor, Mullerian / chemically induced. Mixed Tumor, Mullerian / pathology. Raloxifene Hydrochloride / adverse effects. Selective Estrogen Receptor Modulators / adverse effects. Uterine Neoplasms / chemically induced. Uterine Neoplasms / pathology
  • [MeSH-minor] Biopsy, Needle. Chemotherapy, Adjuvant. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Hysterectomy / methods. Immunohistochemistry. Middle Aged. Neoplasm Staging. Osteoporosis, Postmenopausal / diagnosis. Osteoporosis, Postmenopausal / drug therapy. Ovariectomy / methods. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863610.001).
  • [ISSN] 0029-7844
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Selective Estrogen Receptor Modulators; 4F86W47BR6 / Raloxifene Hydrochloride
  •  go-up   go-down


8. Wong L, See HT, Khoo-Tan HS, Low JS, Ng WT, Low JJ: Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed müllerian tumors of the uterus. Int J Gynecol Cancer; 2006 May-Jun;16(3):1364-9
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined adjuvant cisplatin and ifosfamide chemotherapy and radiotherapy for malignant mixed müllerian tumors of the uterus.
  • The role of adjuvant therapy for malignant mixed müllerian tumors of the uterus has not been established.
  • Our aim was to review our experience with sequential adjuvant therapy using cisplatin and ifosfamide chemotherapy and radiotherapy after surgical staging.
  • The Cox proportional hazard regression model was used to assess the effect of treatment on survival after adjustment for age and stage.
  • Twenty-eight patients received adjuvant chemotherapy and 28 patients had adjuvant radiotherapy.
  • Twenty-one patients underwent sequential adjuvant chemotherapy and radiotherapy.
  • Tumor recurrence occurred in 14 patients at a median duration of 10 months.
  • Patients who underwent sequential adjuvant therapy had an improved survival compared with patients who did not follow the protocol (P= 0.024).
  • Our results with sequential adjuvant therapy are encouraging and justify future randomized trials.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Ifosfamide / administration & dosage. Mixed Tumor, Mullerian / drug therapy. Mixed Tumor, Mullerian / radiotherapy. Uterine Neoplasms / drug therapy. Uterine Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy / statistics & numerical data. Disease-Free Survival. Drug Evaluation. Female. Humans. Hysterectomy. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Postoperative Period. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16803531.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


9. Shi Y, Liu Z, Peng Z, Liu H, Yang K, Yao X: The diagnosis and treatment of Mullerian adenosarcoma of the uterus. Aust N Z J Obstet Gynaecol; 2008 Dec;48(6):596-600
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The diagnosis and treatment of Mullerian adenosarcoma of the uterus.
  • BACKGROUND: Adenosarcoma of the uterus is one of the rare types of gynaecological malignant tumours.
  • AIM: To improve the level of diagnosis and treatment of Mullerian adenosarcoma of the uterus.
  • METHODS: The medical data of nine patients with Mullerian adenosarcoma of the uterus who were treated from May 1995 to March 2006 in our hospital were analysed retrospectively.
  • The analysis focused on clinicopathological features, treatment and prognosis.
  • RESULTS: Patients typically presented with abnormal uterine bleeding, pain in the lower abdomen, enlargement of the uterus, a mass in the uterine cavity and/or a cervical neoplasm.
  • The primary diagnostic rate was 33.3% and the average interval from symptom onset to final diagnosis was 13 months and eight weeks for pre- and postmenopausal patients, respectively.
  • CONCLUSIONS: The most common symptom of adenosarcoma of the uterus is abnormal uterine bleeding.
  • Surgery is the primary treatment, and chemotherapy may be somewhat beneficial.
  • [MeSH-major] Adenosarcoma / diagnosis. Mixed Tumor, Mullerian / diagnosis. Neoplasms, Germ Cell and Embryonal / diagnosis. Uterine Cervical Neoplasms / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Adult. Age Factors. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19133051.001).
  • [ISSN] 1479-828X
  • [Journal-full-title] The Australian & New Zealand journal of obstetrics & gynaecology
  • [ISO-abbreviation] Aust N Z J Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


10. Ulbricht LJ, Kunert M, Gremmler B, Evagelopoulos N, Krian A, Moege J: Intracardiac metastasis of a Malignant Mixed Mullerian tumor (MMMT): progressive dyspnoea due to obstruction of the left atrium and the left ventricle without left ventricular dysfunction or primary lung disease. Wien Med Wochenschr; 2009;159(13-14):355-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracardiac metastasis of a Malignant Mixed Mullerian tumor (MMMT): progressive dyspnoea due to obstruction of the left atrium and the left ventricle without left ventricular dysfunction or primary lung disease.
  • Malignant Mixed Mullerian tumors (MMMT) are rare gynecological tumors.
  • Even with surgical treatment, chemotherapy, and/or radiotherapy, outcome is poor.
  • In a 61-year-old female patient who had undergone surgical resection of a Mullerian tumor of the uterus 26 months prior to being admitted to our department, we found an obstructing left atrial mass.
  • Histopathologic assessment of this lesion after surgical resection revealed a Mullerian tumor metastasis.
  • [MeSH-major] Dyspnea / etiology. Heart Atria. Heart Neoplasms / diagnosis. Heart Ventricles. Mixed Tumor, Mullerian / diagnosis. Mixed Tumor, Mullerian / secondary. Uterine Neoplasms / diagnosis. Ventricular Function, Left / physiology
  • [MeSH-minor] Disease Progression. Echocardiography. Echocardiography, Transesophageal. Female. Humans. Middle Aged. Palliative Care. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Breathing Problems.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Oncol. 2005;44(7):756-60 [16227168.001]
  • [Cites] Gynecol Oncol. 1998 Aug;70(2):303-7 [9740711.001]
  • [Cites] Gynecol Obstet Invest. 1997;44(3):214-6 [9359652.001]
  • [Cites] Gynecol Oncol. 1991 Nov;43(2):186-90 [1660435.001]
  • [Cites] Int Surg. 1989 Jul-Sep;74(3):195-7 [2558083.001]
  • [Cites] Breast J. 2002 Sep-Oct;8(5):305-6 [12199759.001]
  • [Cites] Cancer. 1986 Jan 1;57(1):155-9 [3000571.001]
  • [Cites] Am J Surg Pathol. 1979 Apr;3(2):125-35 [231382.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):786-96 [14967435.001]
  • [Cites] Gynecol Oncol. 1988 Jul;30(3):422-6 [2839396.001]
  • [Cites] Acta Obstet Gynecol Scand. 1986;65(7):811-2 [3811858.001]
  • [Cites] Singapore Med J. 2002 Sep;43(9):452-6 [12568422.001]
  • [Cites] JOP. 2006 Jan 11;7(1):66-9 [16407622.001]
  • (PMID = 19652943.001).
  • [ISSN] 1563-258X
  • [Journal-full-title] Wiener medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Wien Med Wochenschr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


11. Ko ML, Jeng CJ, Huang SH, Shen J, Tzeng CR, Chen SC: Primary peritoneal carcinosarcoma (malignant mixed mullerian tumor): Report of a case with five-year disease free survival after surgery and chemoradiation and a review of literature. Acta Oncol; 2005;44(7):756-60
Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary peritoneal carcinosarcoma (malignant mixed mullerian tumor): Report of a case with five-year disease free survival after surgery and chemoradiation and a review of literature.
  • Malignant mixed mullerian tumors (MMMTs), also known as carcinosarcoma because they contain both carcinomatous and sarcomatous elements are aggressive tumors, which usually arise in the uterus and ovary.
  • Here we report a case of a primary carcinosarcoma of the pelvic peritoneum with five-year disease-free survival after managing the patient with surgery, chemotherapy and radiotherapy.
  • [MeSH-major] Carcinosarcoma / diagnosis. Mixed Tumor, Malignant / diagnosis. Mixed Tumor, Mullerian / diagnosis. Peritoneal Neoplasms / diagnosis. Peritoneal Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Disease-Free Survival. Female. Humans. Laparotomy. Middle Aged. Radiotherapy Dosage

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16227168.001).
  • [ISSN] 0284-186X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Lee SH, Kim J, Kim JH, Lee KH, Park JS, Hur SY: Malignant mixed mullerian tumor of the cervix including components of a rhabdomyosarcoma: case report and literature review. Eur J Gynaecol Oncol; 2010;31(4):462-6
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed mullerian tumor of the cervix including components of a rhabdomyosarcoma: case report and literature review.
  • Malignant mixed mesodermal tumors (MMMTs) are composed of carcinomatous and sarcomatous components and have an aggressive metastatic potential, resulting in a poor prognosis.
  • MMMTs of gynecologic origin typically arise from either the ovary or the uterus, and MMMTs of the cervix are extremely rare.
  • Due to the rarity of MMMTs arising from the cervix, there is no consensus regarding treatment, prognosis, and outcome; however, aggressive surgical cytoreduction, combined with adjuvant platinum-based chemotherapy and/or radiotherapy, is recommended as the treatment of choice for MMMTs of the cervix.
  • Cervical MMMTs are more often confined to the uterus at the time of diagnosis and frequently have non-glandular epithelial components.
  • [MeSH-major] Mixed Tumor, Mullerian / pathology. Rhabdomyosarcoma / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Combined Modality Therapy. Female. Humans. Immunohistochemistry. Middle Aged

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20882897.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  •  go-up   go-down


13. Chao KC, Wang PH, Chang CC, Lai CR, Ng HT: Establishment and characterization of a cell line, MT-213-VGH, isolated from a mixed müllerian tumor of the uterus. Acta Cytol; 2001 Sep-Oct;45(5):683-90
Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of a cell line, MT-213-VGH, isolated from a mixed müllerian tumor of the uterus.
  • OBJECTIVE: To establish a cell line from a woman with malignant mixed müllerian tumor of the uterus and to examine the biologic properties of this cell line (MT-213-VGH).
  • Histologic staining of mixed müllerian (mesodermal) tumor (MMMT) cells was performed with May-Grünwald-Giemsa and hematoxylin and eosin stain.
  • After more than 20 passages, cells were used to estimate the population-doubling time and colony-forming efficiency of MMMT cells.
  • The cell line exhibited considerable variation in the degree of sensitivity to diverse chemotherapy drugs in vitro.
  • CONCLUSION: The establishment and availability of the number cell line MT-213-VGH for a malignant mixed müllerian tumor of the uterus should assist in research on new methods of managing this type of gynecologic cancer.
  • [MeSH-major] Mixed Tumor, Mullerian. Tumor Cells, Cultured. Uterine Neoplasms

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11575644.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


14. Powell MA, Filiaci VL, Rose PG, Mannel RS, Hanjani P, DeGeest K, Miller BE, Susumu N, Ueland FR: A phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: A Gynecologic Oncology Group (GOG) study. J Clin Oncol; 2009 May 20;27(15_suppl):5515

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: A Gynecologic Oncology Group (GOG) study.
  • : 5515 Background: Both platinum and taxane compounds have demonstrated activity in uterine carcinosarcoma (malignant mixed Mullerian tumor).
  • METHODS: Eligible patients had advanced stage (III or IV), persistent, or recurrent measurable disease with histologic confirmation of the primary tumor, no prior chemotherapy, and a GOG Performance Status of 2 or better.
  • Patients received the combination of paclitaxel 175 mg/m2 IV over 3 hours plus carboplatin (AUC 6) IV over 30 minutes every 3 weeks until disease progression or adverse effects prohibit further therapy.
  • This study used an optimal but flexible two-stage design with early stopping guidelines intended to limit patient accrual to inactive treatments.
  • RESULTS: Fifty-five patients were entered on study with 9 being excluded from analysis; 7 with unconfirmed diagnosis at CPR and 2 were never treated.
  • Treatment was generally tolerated with expected hematologic toxicity and minimal non-hematologic grade 4 toxicity (1 cardiovascular and 2 pain) with 59% of patients completing 6 or more cycles of chemotherapy.
  • CONCLUSIONS: Paclitaxel plus carboplatin demonstrates anti-tumor activity against uterine carcinosarcoma with acceptable toxicity and warrants further evaluation in phase III randomized trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962461.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Gallardo A, Prat J: Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma. Am J Surg Pathol; 2009 Feb;33(2):278-88
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma.
  • Mullerian adenosarcomas are rare mixed tumors of low malignant potential that occur mainly in the uterus and also in extrauterine locations.
  • Treatment was known in 50 patients: 10 had polypectomy, 1 cone biopsy, and 39 hysterectomy, which was accompanied by bilateral salpingo-oophorectomy in 24 and lymphadenectomy in 4.
  • Five patients had radiotherapy and 2 of them had chemotherapy.
  • The tumor of the fallopian tube was stage IC, and the tumors of the vagina and recto-uterine pouch were confined to their site of origin.
  • Six developed metastases and 5 of them died of tumor.
  • The finding of such cases, which raises the controversy of whether or not adenofibroma exists as a tumor entity, prompted us to make a comparative immunohistochemical analysis of 23 typical adenosarcomas, 8 adenosarcomas with sarcomatous overgrowth, and 29 benign and malignant related lesions, including 7 clinically benign adenofibromas.
  • Adenosarcomas with sarcomatous overgrowth showed strong immunoreaction for Ki-67 and p53 and loss of CD10 and progesterone receptors immunostaining; in contrast, the immunoreaction for these tumor markers in typical adenosarcomas without sarcomatous overgrowth was similar to that of adenofibromas associated with favorable outcome and other benign lesions such as endometrial polyps and endometriosis.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Mitotic Index. Neoplasm Staging. Tissue Array Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941402.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


16. Callister M, Ramondetta LM, Jhingran A, Burke TW, Eifel PJ: Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys; 2004 Mar 1;58(3):786-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome.
  • PURPOSE: To determine the survival outcomes, prognostic factors, and patterns of failure in patients with malignant mixed Müllerian tumor (MMMT) of the uterus.
  • METHODS AND MATERIALS: Between 1954 and 1998, 300 patients with clinical Stage I-III MMMT of the uterus were treated with curative intent at The University of Texas M. D.
  • Their hospital records were reviewed to obtain patient and tumor characteristics; details of surgery, radiotherapy (RT), and chemotherapy; and long-term outcome.
  • Forty-eight patients received adjuvant chemotherapy.
  • However, patients treated with pelvic RT had a longer mean time to any distant relapse (17.3 vs. 7.0 months, p = 0.001) than patients treated with surgery alone.
  • The use of adjuvant chemotherapy did not correlate with the survival rate or rate of distant metastasis.
  • As more effective systemic chemotherapy is developed to control microscopic distant disease, the role of RT in controlling locoregional disease in the pelvis and abdomen may become more important.
  • Future research should consider programs that integrate surgery, RT, and chemotherapy to maximize the probability of cure.
  • [MeSH-major] Mixed Tumor, Malignant / mortality. Mixed Tumor, Mullerian / mortality. Uterine Neoplasms / mortality
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Chemotherapy, Adjuvant. Female. Humans. Middle Aged. Postmenopause. Postoperative Complications. Prognosis. Radiation Injuries / pathology. Radiotherapy, Adjuvant. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14967435.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Saim M, Cote JF, Morel O, Malartic C, Akerman G, Gray F, Barranger E: [Malignant mixed müllerian tumor of the uterus following tamoxifen for breast cancer: case report]. Gynecol Obstet Fertil; 2008 Feb;36(2):166-8
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant mixed müllerian tumor of the uterus following tamoxifen for breast cancer: case report].
  • [Transliterated title] Tumeur müllérienne mixte de l'utérus après traitement par tamoxifène pour cancer du sein: à propos d'un cas.
  • Tamoxifen is an antioestrogen widely used in the breast cancer treatment.
  • Since 1988, few cases of malignant mixed müllerian tumors following tamoxifen were described.
  • We report a new case of uterine malignant mixed müllerian tumor four years after the end of tamoxifen for breast cancer.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Mixed Tumor, Mullerian / chemically induced. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced


18. Dusenbery KE, Potish RA, Judson P: Limitations of adjuvant radiotherapy for uterine sarcomas spread beyond the uterus. Gynecol Oncol; 2004 Jul;94(1):191-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limitations of adjuvant radiotherapy for uterine sarcomas spread beyond the uterus.
  • Seven also received adjuvant chemotherapy.
  • Patients with mixed mullerian tumors had overall and disease-free survivals of 31% at 1 year and 23% at 5 years.
  • Although abdominal failures are common in women with mixed mullerian tumors, translation of higher radiation dosage to cure is unproven, and the majority of failures have a distant component.
  • Until effective systemic therapy is developed, the prognosis of uterine sarcomas with any spread beyond the uterus will remain poor.
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Leiomyosarcoma / pathology. Leiomyosarcoma / radiotherapy. Leiomyosarcoma / secondary. Leiomyosarcoma / surgery. Middle Aged. Mixed Tumor, Mullerian / pathology. Mixed Tumor, Mullerian / radiotherapy. Mixed Tumor, Mullerian / secondary. Mixed Tumor, Mullerian / surgery. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / radiotherapy. Peritoneal Neoplasms / secondary. Peritoneal Neoplasms / surgery. Radiotherapy, Adjuvant. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15262141.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Manolitsas TP, Wain GV, Williams KE, Freidlander M, Hacker NF: Multimodality therapy for patients with clinical Stage I and II malignant mixed Müllerian tumors of the uterus. Cancer; 2001 Apr 15;91(8):1437-43
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multimodality therapy for patients with clinical Stage I and II malignant mixed Müllerian tumors of the uterus.
  • BACKGROUND: The role of adjuvant therapy in the management of patients with malignant mixed Müllerian tumors (MMMT) of the uterus has not been defined.
  • The outcome of planned multimodality therapy for patients with apparent early stage disease was assessed.
  • METHODS: A pilot study was performed on 38 patients with clinical Stage I or II MMMTs of the uterus who were offered treatment according to a standard protocol.
  • The protocol consisted of removal of the uterus, fallopian tubes, and ovaries and surgical staging followed by tailored radiation therapy and chemotherapy, consisting of cisplatin and epirubicin.
  • The mean time to death from disease was 26 months (range, 7-87 months).
  • The survival rate for those patients who completed treatment according to the multimodality protocol was 95% (20 of 21 patients), with a disease free survival rate of 90% (19 of 21 patients).
  • The overall survival of patients who did not receive the recommended treatment protocol for various reasons was 47% (8 of 17 patients).
  • An analysis of survival curves demonstrated that there was a significant survival advantage for those patients who completed the treatment according to the multimodality protocol (P = 0.01).
  • CONCLUSIONS: In this pilot study, patients with clinical Stage I or II MMMTs who underwent surgical staging and aggressive adjuvant radiation and chemotherapy had an excellent survival rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mixed Tumor, Mullerian / radiotherapy. Mixed Tumor, Mullerian / surgery. Uterine Neoplasms / radiotherapy. Uterine Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Combined Modality Therapy. Epirubicin / administration & dosage. Female. Humans. Hysterectomy. Middle Aged. Ovariectomy. Radiotherapy, Adjuvant. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 American Cancer Society.
  • (PMID = 11301390.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


20. Miller DS, Blessing JA, Schilder J, Munkarah A, Lee YC: Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol; 2005 Aug;98(2):217-21
Hazardous Substances Data Bank. Topotecan .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study.
  • OBJECTIVES: To estimate the antitumor activity of topotecan in patients with persistent or recurrent carcinosarcoma (malignant mixed mullerian tumors) of the uterus and to determine the nature and degree of toxicity of topotecan in this cohort of patients.
  • MATERIALS AND METHODS: Eligible patients had measurable advanced or recurrent carcinosarcoma of the uterus.
  • Topotecan at a target dose of 1.5 mg/m(2) was administered IV daily for 5 days, every 3 weeks, until progression of disease or adverse affects prohibited further therapy.
  • Patient characteristics included a median age of 65, with 33% having prior radiation and 92% having prior chemotherapy.
  • Patients received from 1 to 21 (with a median of 2) courses of treatment.
  • Three (6%) patients developed neutropenic sepsis and died shortly after their first treatment cycle.
  • CONCLUSION: Topotecan at this dose and schedule does not appear to have major activity in patients with advanced or recurrent uterine carcinosarcoma previously treated with chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinosarcoma / drug therapy. Mixed Tumor, Mullerian / drug therapy. Topotecan / therapeutic use. Uterine Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15975641.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / CA 37517
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7M7YKX2N15 / Topotecan
  •  go-up   go-down


21. Ozguroglu M, Bilici A, Ilvan S, Turna H, Atalay B, Mandel N, Sahinler I: Determining predominating histologic component in malignant mixed müllerian tumors: is it worth it? Int J Gynecol Cancer; 2008 Jul-Aug;18(4):809-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Determining predominating histologic component in malignant mixed müllerian tumors: is it worth it?
  • Malignant mixed müllerian tumors (MMMT) are highly aggressive tumors, usually diagnosed in advanced stage.
  • Cases of MMMT derive from either ovary or uterus.
  • In our study, we investigated the role of carcinomatous and sarcomatous component on response to chemotherapy and disease outcome.
  • All the paraffin specimens were reevaluated according to the histopathologic features (primary site and percentages of carcinomatous and sarcomatous component) and the effect of predominant histologic type on response to treatment.
  • Primary tumor sites were ovary and endometrium in 36% and 64% of patients, respectively.
  • Ten of 25 patients (40%) were treated with a combination chemotherapy regimen of cisplatin-ifosfamide (PI) and 7 patients (28%) were treated with paclitaxel-carboplatin (PC) protocol.
  • Despite chemotherapy, 17.6% of patients had progressive disease.
  • The remaining 13 patients (54.2%) responded to chemotherapy.
  • Predominating histopathologic feature (carcinoma or sarcoma) should be taken into consideration in predicting the response and planning the chemotherapy regimen.
  • [MeSH-major] Mixed Tumor, Mullerian / diagnosis. Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / diagnosis. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Planning Techniques. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892455.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Kajo K, Zubor P, Spacek J, Ryska A: Carcinosarcoma of the uterus with melanocytic differentiation. Pathol Res Pract; 2007;203(10):753-8
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carcinosarcoma of the uterus with melanocytic differentiation.
  • A case of a 54-year-old woman with a history of treatment for breast carcinoma is reported.
  • The patient presented with a uterine tumor showing histological, immunohistochemical, and ultrastructural features of an extremely rare CS, with signs of melanocytic differentiation.
  • The lesion was a 7.0 x 5.6 cm polypoid tumor mass arising from the endometrium and metastasizing in the abdominal cavity as a malignant melanoma - the most aggressive component of CS.
  • Despite adjuvant chemotherapy, she died 8 months after the initial diagnosis due to the metastatic spread of CS.
  • We discuss a possible pathogenesis of this lesion and the role of tamoxifen in the tumor development as well.
  • [MeSH-major] Abdominal Neoplasms / secondary. Carcinosarcoma / pathology. Cell Differentiation. Melanocytes / ultrastructure. Melanoma / secondary. Mixed Tumor, Mullerian / pathology. Uterine Neoplasms / pathology
  • [MeSH-minor] Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Immunohistochemistry. Microscopy, Electron. Middle Aged

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17656038.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


23. Le Bouëdec G, Penault-Llorca F, de Latour M, Tortochaux J, Dauplat J: [Mixed müllerian tumours of the endometrium. About four cases developed on tamoxifen treatment]. Gynecol Obstet Fertil; 2003 Sep;31(9):733-8
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mixed müllerian tumours of the endometrium. About four cases developed on tamoxifen treatment].
  • We report four cases of mixed müllerian tumors of the endometrium arising in postmenopausal women taking tamoxifen for breast carcinoma.
  • Various histopathologic features were encountered: one müllerian adenosarcoma and three malignant mixed müllerian tumors so called carcinosarcomas (in one case the sarcomatous component was homologous composed of tissues normally found in the uterus, while the others were heterologous because they were containing some elements normally not found in the uterus).
  • Concern has been raised about prolonged tamoxifen treatment and subsequent occurrence of endometrial adenocarcinoma.
  • Then, attention has been drawn through high-risk histologic subtypes including poorly differentiated patterns, uterine sarcomas and such mixed müllerian tumors.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Endometrial Neoplasms / chemically induced. Mixed Tumor, Mullerian / chemically induced. Tamoxifen / adverse effects
  • [MeSH-minor] Aged. Aged, 80 and over. Breast Neoplasms / drug therapy. Female. Humans. Middle Aged. Postmenopause

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Obstet Fertil. 2004 Dec;32(12):1091-2 [15589790.001]
  • (PMID = 14499719.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


24. Dusenbery KE, Potish RA, Argenta PA, Judson PL: On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus. Am J Clin Oncol; 2005 Jun;28(3):295-300
Hazardous Substances Data Bank. DACTINOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] On the apparent failure of adjuvant pelvic radiotherapy to improve survival for women with uterine sarcomas confined to the uterus.
  • This retrospective report analyzes patterns of failure, survival, and toxicity in 42 women with stage I and 7 patients with stage II uterine sarcomas treated from 1972 through 1998 to identify patients likely to benefit from pelvic or abdominal radiotherapy and chemotherapy.
  • Four of these patients also received adjuvant chemotherapy.
  • There were 20 leiomyosarcomas, 18 homologous mixed mullerian tumors, and 11 heterologous mixed mullerian tumors.
  • Disease-free survivals for mixed mullerian tumors were 65% at 5 years and 61% at 15 years.
  • Acute toxicity was acceptable as measured by a median 1-kg weight loss from radiotherapy and a 2% rate of failure to complete therapy.
  • Although the frequent occurrence of peritoneal failures suggests a role for prophylactic abdominal radiation for mixed mullerian tumors, more effective systemic therapy is necessary to substantially increase the chance of cure for women with early-stage uterine sarcomas.
  • [MeSH-minor] Abdominal Neoplasms / mortality. Abdominal Neoplasms / prevention & control. Abdominal Neoplasms / secondary. Antineoplastic Agents / therapeutic use. Brachytherapy. Chemotherapy, Adjuvant. Combined Modality Therapy. Dactinomycin / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Humans. Hysterectomy / methods. Ifosfamide / therapeutic use. Intestinal Obstruction / etiology. Leiomyosarcoma / mortality. Leiomyosarcoma / radiotherapy. Leiomyosarcoma / secondary. Leiomyosarcoma / surgery. Life Tables. Mixed Tumor, Mullerian / mortality. Mixed Tumor, Mullerian / radiotherapy. Mixed Tumor, Mullerian / secondary. Mixed Tumor, Mullerian / surgery. Neoplasm Staging. Pelvic Neoplasms / mortality. Pelvic Neoplasms / prevention & control. Pelvic Neoplasms / secondary. Peritoneal Neoplasms / mortality. Peritoneal Neoplasms / prevention & control. Peritoneal Neoplasms / secondary. Radiation Injuries / etiology. Radiotherapy, Adjuvant / adverse effects. Retrospective Studies. Survival Analysis. Survival Rate. Treatment Failure

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15923804.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 1CC1JFE158 / Dactinomycin; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide
  • [Number-of-references] 18
  •  go-up   go-down


25. del Carmen MG, Lovett D, Goodman A: A case of Müllerian adenosarcoma of the uterus treated with liposomal doxorubicin. Gynecol Oncol; 2003 Mar;88(3):456-8
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of Müllerian adenosarcoma of the uterus treated with liposomal doxorubicin.
  • OBJECTIVE: We report on a case of uterine a denosarcoma responsive to treatment with liposomal doxorubicin (Doxil).
  • RESULTS: A 69-year-old woman presented to our institution with dehydration and failure to thrive, and recurrent uterine adenosarcoma, 9 months after initial diagnosis.
  • She had undergone total abdominal hysterectomy and bilateral salpingo-oophorectomy at the time of diagnosis, followed by two cycles of Ifosfamide and treatment with megestrol acetate.
  • She underwent treatment with six cycles of liposomal doxorubicin with a marked response.
  • Given the development of Grade II hand-foot syndrome, liposomal doxorubicin was stopped and two cycles of carboplatin/paclitaxel chemotherapy were administered.
  • The patient developed disease recurrence after a 7-month disease-free interval and 2 years after initial diagnosis.
  • Following another two cycles of liposomal doxorubicin, the patient underwent another cytoreductive procedure for recurrent disease.
  • Two months later, the patient expired, 29 months after diagnosis and 20 months after initial treatment with liposomal doxorubicin chemotherapy.
  • CONCLUSIONS: Liposomal doxorubicin appears to be active in the treatment of recurrent uterine adenosarcoma.
  • [MeSH-major] Adenosarcoma / drug therapy. Doxorubicin / therapeutic use. Mixed Tumor, Mullerian / drug therapy. Uterine Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12648604.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


26. Hines BJ, Porges RF, Mittal K, Muggia FM, Curtin JP: Use of medroxyprogesterone acetate in the treatment of Müllerian adenosarcoma: a case report. Gynecol Oncol; 2002 Apr;85(1):192-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of medroxyprogesterone acetate in the treatment of Müllerian adenosarcoma: a case report.
  • These tumors are relatively insensitive to chemotherapy and radiation and are primarily treated by surgical resection.
  • We report a case of müllerian adenosarcoma arising outside of the uterus from a background of endometriosis treated with a combination of surgical resection and medroxyprogesterone acetate.
  • After suboptimal tumor dubulking surgery she was treated with medroxyprogesterone acetate.
  • CONCLUSION: Medroxyprogesterone acetate may be a useful drug in the treatment of advanced müllerian adenosarcoma.
  • [MeSH-major] Adenosarcoma / drug therapy. Antineoplastic Agents, Hormonal / therapeutic use. Genital Neoplasms, Female / drug therapy. Medroxyprogesterone Acetate / therapeutic use. Mixed Tumor, Mullerian / drug therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Endometriosis / complications. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11925144.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


27. Matulonis U, Campos S, Duska L, Fuller A, Berkowitz R, Gore S, Roche M, Colella T, Lee H, Seiden MV, Gynecologic Oncology Research Program at Dana Farber/Partners Cancer Care, Dana Farber-Harvard Cancer Care: A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. Gynecol Oncol; 2003 Nov;91(2):293-8
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies.
  • OBJECTIVES: In an effort to improve the results of primary chemotherapy for müllerian malignancies a novel chemotherapy program was piloted that delivered three sequential chemotherapy doublets.
  • After therapy, all women were clinically staged and evaluated by second-look laparoscopy/laparotomy (SLO) if clinical staging was negative for residual disease.
  • Forty-four women had either ovarian cancer or primary peritoneal carcinoma with 3 women diagnosed with fallopian tube carcinoma and 2 with papillary serous carcinoma of the uterus.
  • Thirty-nine of 49 (80%) patients completed therapy.
  • A total of 283 cycles of chemotherapy were delivered with acceptable toxicities.
  • Thirty-nine women completed all cycles of treatment.
  • CONCLUSIONS: Treatment with this sequential doublet regimen is feasible with a 38% pathologic CR rate.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Deoxycytidine / analogs & derivatives. Genital Neoplasms, Female / drug therapy. Mixed Tumor, Mullerian / drug therapy
  • [MeSH-minor] Carboplatin / administration & dosage. Carboplatin / adverse effects. Combined Modality Therapy. Cystadenocarcinoma, Papillary / drug therapy. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / surgery. Cystadenocarcinoma, Serous / drug therapy. Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / surgery. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Administration Schedule. Endometrial Neoplasms / drug therapy. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Fallopian Tube Neoplasms / drug therapy. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / surgery. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Middle Aged. Ovarian Neoplasms / drug therapy. Peritoneal Neoplasms / drug therapy. Peritoneal Neoplasms / pathology. Peritoneal Neoplasms / surgery. Topotecan / administration & dosage. Topotecan / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14599858.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  •  go-up   go-down


28. Varras M, Akrivis Ch: Large endometrial polyp with sarcomatous stromal components following long-term tamoxifen treatment for breast cancer: a case report and review of the literature. Eur J Gynaecol Oncol; 2003;24(6):565-8
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large endometrial polyp with sarcomatous stromal components following long-term tamoxifen treatment for breast cancer: a case report and review of the literature.
  • A postoperative computed tomography scan showed many focal hypodense lesions in the hepatic lobes with a well-defined profile suggestive of metastatic disease and the patient was referred for combined chemotherapy.
  • In conclusion, a case of a mesenchymal malignant neoplasm arising in the uterus of a breast cancer patient treated with tamoxifen is reported and its clinical, histological and immunohistochemical features are discussed.
  • [MeSH-major] Breast Neoplasms / drug therapy. Endometrial Neoplasms / diagnosis. Mixed Tumor, Mullerian / diagnosis. Selective Estrogen Receptor Modulators / administration & dosage. Tamoxifen / administration & dosage
  • [MeSH-minor] Aged. Female. Humans. Immunohistochemistry. Polyps / diagnosis. Polyps / pathology. Polyps / surgery. Survivors

  • Genetic Alliance. consumer health - Endometrial cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14658606.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Selective Estrogen Receptor Modulators; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 32
  •  go-up   go-down


29. Bouchardy C, Verkooijen HM, Fioretta G, Sappino AP, Vlastos G: Increased risk of malignant mullerian tumor of the uterus among women with breast cancer treated by tamoxifen. J Clin Oncol; 2002 Nov 1;20(21):4403
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased risk of malignant mullerian tumor of the uterus among women with breast cancer treated by tamoxifen.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Breast Neoplasms / drug therapy. Mixed Tumor, Mullerian / chemically induced. Registries. Tamoxifen / adverse effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] J Clin Oncol. 2002 Jun 1;20(11):2758-60 [12039943.001]
  • (PMID = 12409344.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comment; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


30. Leung F, Terzibachian JJ, Riethmuller D: [Response of F. Leung, J.-J. Terzibachian and D. Riethmuller to the article of M. Saim et al. Malignant mixed Müllerian tumor of the uterus following tamoxifen for breast cancer: case report. Gynecol Obstet Fertil 2008;36:166-8]. Gynecol Obstet Fertil; 2008 Jul-Aug;36(7-8):828-9
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Response of F. Leung, J.-J. Terzibachian and D. Riethmuller to the article of M. Saim et al. Malignant mixed Müllerian tumor of the uterus following tamoxifen for breast cancer: case report. Gynecol Obstet Fertil 2008;36:166-8].
  • [Transliterated title] Réponse de F. Leung, J.-J. Terzibachian et D. Riethmuller à l'article de M. Saim et al. Tumeur müllérienne mixte de l'utérus après traitement par tamoxifène pour cancer du sein: à propos d'un cas. Gynecol Obstet Fertil 2008;36:166-8.
  • [MeSH-major] Breast Neoplasms / drug therapy. Carcinosarcoma / drug therapy. Mixed Tumor, Mullerian / drug therapy. Tamoxifen / therapeutic use
  • [MeSH-minor] Adolescent. Antineoplastic Agents, Hormonal / therapeutic use. Female. Humans

  • Genetic Alliance. consumer health - Malignant mixed Mullerian tumor.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Gynecol Obstet Fertil. 2008 Feb;36(2):166-8 [18249575.001]
  • (PMID = 18656415.001).
  • [ISSN] 1297-9589
  • [Journal-full-title] Gynécologie, obstétrique & fertilité
  • [ISO-abbreviation] Gynecol Obstet Fertil
  • [Language] fre
  • [Publication-type] Comment; Letter
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


31. Chourmouzi D, Boulogianni G, Zarampoukas T, Drevelengas A: Sonography and MRI of tamoxifen-associated müllerian adenosarcoma of the uterus. AJR Am J Roentgenol; 2003 Dec;181(6):1673-5
Hazardous Substances Data Bank. TAMOXIFEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sonography and MRI of tamoxifen-associated müllerian adenosarcoma of the uterus.
  • [MeSH-major] Antineoplastic Agents, Hormonal / adverse effects. Mixed Tumor, Mullerian / chemically induced. Mixed Tumor, Mullerian / diagnosis. Tamoxifen / adverse effects. Uterine Neoplasms / chemically induced. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Breast Neoplasms / drug therapy. Carcinoma, Ductal, Breast / drug therapy. Endosonography. Female. Humans. Magnetic Resonance Imaging. Middle Aged

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14627594.001).
  • [ISSN] 0361-803X
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down






Advertisement